| Literature DB >> 27306901 |
Maria Eduarda Menezes de Siqueira1,2, Eduardo Pozo1,3, Veronica R Fernandes1, Partho P Sengupta1, Karen Modesto1, Sushilkumar Satish Gupta1, Cayetana Barbeito-Caamaño1,4, Jagat Narula1, Valentin Fuster1, Adriano Caixeta2, Javier Sanz5,6.
Abstract
BACKGROUND: Prognosis in pulmonary hypertension (PH) is related to right ventricular (RV) function. Quantification of RV mechanics may offer additive value. The objective of our study is to determine the feasibility and clinical and prognostic value of RV strain analysis by cardiovascular magnetic resonance (CMR) based feature tracking (FT) in PH.Entities:
Keywords: Pulmonary hypertension; Right ventricle; Strain
Mesh:
Year: 2016 PMID: 27306901 PMCID: PMC4910232 DOI: 10.1186/s12968-016-0258-x
Source DB: PubMed Journal: J Cardiovasc Magn Reson ISSN: 1097-6647 Impact factor: 5.364
Fig. 1Schematic representation of myocardial fiber orientation and deformation in 3 orthogonal axis
Fig. 2RV longitudinal strain analysis obtained from a four chamber view. Examples of longitudinal strain measurements in a patient without (bottom) and with pulmonary hypertension (top). The dotted line represents the average strain of the four segments
Demographic, clinical, hemodynamic and cardiac magnetic resonance data according to the presence of pulmonary hypertension and right ventricular ejection fraction
| Variable | Total ( | Group A (No PH and RVEF ≥50 %) ( | Group B (PH and RVEF ≥50 %) ( | Group C (PH and RVEF < 50 %) ( |
|
|---|---|---|---|---|---|
| Demographic data | |||||
| Age (yrs) | 52.2 ± 12 | 52.6 ± 13 | 55 ± 12 | 51 ± 12 | 0.37 |
| Female sex | 81 (73.6 %) | 15 (88.2 %) | 22 (84.6 %) | 44 (65.7 %) | 0.06 |
| Body surface area (m2) | 1.79 ± 0.23 | 1.74 ± 0.17 | 1.76 ± 0.23 | 1.8 ± 0.24 | 0.369 |
| Cardiovascular risk factors | |||||
| Diabetes | 12 (10.9 %) | 0 | 4 (15.4 %) | 8 (11.9 %) | 0.26 |
| Hypertension | 24 (21.8 %) | 3 (17.6 %) | 8 (30.8 %) | 13 (19.4 %) | 0.44 |
| Hyperlipidemia | 17 (15.5 %) | 3 (17.6 %) | 4 (15.4 %) | 10 (14.9 %) | 0.96 |
| Smoking history | 8 (7.3 %) | 0 | 3 (11.5 %) | 5 (7.5 %) | 0.24 |
| Medications | |||||
| Beta blockers | 14 (12.7 %) | 1 (5.8 %) | 2 (8 %) | 11 (18 %) | 0.12 |
| Calcium channel blockers | 34 (30.9 %) | 0 | 16 (61.5 %) | 18 (26.9 %) | <0.001** ŧ |
| Diuretics | 66 (60 %) | 2 (13.3 %) | 13 (52 %) | 51 (83.6 %) | <0.001** ŧ& |
| Anticoagulants | 38 (34.5 %) | 2 (11.7 %) | 8 (30.7 %) | 28 (41.7 %) | 0.053& |
| ERAs | 31 (28.2 %) | 0 | 4 (15.7 %) | 27 (40.2 %) | <0.001ŧ& |
| Prostanoids | 34 (30.9 %) | 0 | 8 (30.7 %) | 26 (38.8 %) | 0.03& |
| PDIs | 48 (43.6 %) | 0 | 11 (42.3 %) | 37 (55.2 %) | <0.001**& |
| Digoxin | 38 (34.5 %) | 2 (11.7 %) | 4 (15.4 %) | 32 (47.7 %) | 0.001ŧ & |
| Corticosteroids | 25 (22.7 %) | 2 (11.7 %) | 4 (15.4 %) | 19 (28.3 %) | 0.201 |
| NYHA functional class ≥2 | 90 (81.8 %) | 2 (11.7 %) | 22 (84.6 %) | 62 (92.5 %) | <0.001**& |
| Hemodynamic data | |||||
| Systolic aortic pressure (mm Hg) | 122.1 ± 19 | 122.7 ± 20.3 | 132 ± 19.2 | 118.2 ± 18.1 | 0.009ŧ |
| PAWP (mm Hg) | 9.8 ± 4.1 | 8.5 ± 2.8 | 11.5 ± 4.7 | 9.55 ± 4 | 0.05 |
| Cardiac index (L/min/m2) | 3.2 ± 1.1 | 3.71 ± 1 | 3.77 ± 1.5 | 2.91 ± 0.9 | 0.001ŧ& |
| Systolic PA pressure (mm Hg) | 63.6 ± 24.7 | 29.6 ± 3.8 | 50.8 ± 13.1 | 72.1 ± 27.9 | <0.001& |
| Mean PA pressure (mm Hg) | 39.6 ± 14.9 | 17.1 ± 3.3 | 36.3 ± 10.6 | 46.6 ± 11.7 | <0.001**ŧ& |
| RA pressure (mm Hg) | 6 [23.1–35.6] | 4 [3–6] | 6 [4–10] | 7 [5–14] | 0.006**& |
| PVRI (Woods units × m2) | 5.8 [2.7–9.3] | 1.8 [1.2–2.4] | 4 [2.1–8] | 6.9 [5–10.4] | <0.001**ŧ& |
| PA oxygen saturation (%) | 64.7 ± 10.97 | 72.6 ± 4.8 | 68.6 ± 6.9 | 61.1 ± 11.8 | <0.001ŧ& |
| Cardiac magnetic resonance | |||||
| LVEF (%) | 58.9 ± 9.8 | 63.3 ± 6 | 64.6 ± 5.2 | 55.5 ± 10.5 | <0.001ŧ& |
| LVEDVi (mL/m2) | 66.6 ± 17.4 | 69 ± 12.5 | 73 ± 25 | 63 ± 18.5 | 0.07 |
| LVESVi (mL/m2) | 27.6 ± 9.9 | 25.3 ± 6.6 | 26.1 ± 7 | 28.2 ± 11.3 | 0.30 |
| RVEF (%) | 42.15 ± 13.7 | 57.5 ± 4.6 | 55.2 ± 4.8 | 33.1 ± 9.4 | <0.001ŧ& |
| RVEDVi (mL/m2) | 98.8 [75.3–127] | 73.1 [57.6–81.1] | 85.4 [71.7–99] | 116.4 [98–156] | <0.001**ŧ& |
| RVESVi (mL/m2) | 56 [36.9–87.3] | 28.7 [23.1–35.6] | 39.6 [33.8–47.9] | 78.6 [56.1–103] | <0.001**ŧ& |
| RV mass index (g/m2)* | 25 [17.4–33] | 15.5 [13.4–17.4] | 18.8 [14.1–24.3] | 30.2 [23.7–35.6] | <0.001**ŧ & |
| LGE | 44 (40 %) | 1 (5.9 %) | 3 (11.5 %) | 38 (56.7 %) | <0.001ŧ& |
| RA area (mm2) | 24.54 ± 8.9 | 17.9 ± 3.3 | 21.9 ± 7 | 27.1 ± 9.5 | 0.001ŧ& |
| Clinical outcomes | |||||
| Death/transplant/worse NYHA class | 78 (70.9 %) | 4 (23.5 %) | 12 (46.1 %) | 62 (92.5 %) | <0.001ŧ& |
Values are mean ± standard deviation, n (%), or median [interquartile range]
ERA endothelin receptor antagonist, LGE late gadolinium enhancement, LVEF left ventricular ejection fraction, LVEDVi left ventricular end-diastolic volume index, LVESVi left ventricular end-systolic volume index, NYHA New York Heart Association, PA pulmonary artery, PAWP pulmonary artery wedge pressure, PDI phosphodiesterase inhibitor, PVRI pulmonary vascular resistance index, RA right atrium, RVEDVi right ventricular end-diastolic volume index, RVEF right ventricular ejection fraction, RVESVi right ventricular end-systolic volume index
**Statistically significant differences between group A (control group) and group B
ŧ Statistically significant differences between group B and group C
& Statistically significant differences between group A and group C
Global right ventricular strain and strain rate
| Strain Parameter | Total ( | Group A (No PH and RVEF ≥50 %) ( | Group B (PH and RVEF ≥50 %) ( | Group C (PH and RVEF < 50 %) ( |
|
|---|---|---|---|---|---|
| GLS (%) | -15.85 ± 6.4 | -22.10 ± 4.7 | -20.10 ± 5.3 | -12.56 ± 4.8 | <0.001bc |
| GCS (%) | -11.21 ± 4.9 | -16.43 ± 4.7 | -14.12 ± 3.5 | -8.72 ± 3.5 | <0.001bc |
| GLSR (s-1) | -1.09 ± 0.4 | -1.46 ± 0.4 | -1.33 ± 0.3 | -0.89 ± 0.3 | <0.001bc |
| GCSR (s-1) | -0.76 [-0.9 - (-0.5)] | -1.12 [-1.3 - (-0.9)] | -0.92 [-1.0 - (-0.7)] | -0.63 [-0.7 - (-0.4)] | <0.001abc |
Values are mean ± standard deviation or median [interquartile range]
GCS global circumferential strain, GCSR global circumferential strain rate, GLS global longitudinal strain, GLSR global longitudinal strain rate, PH pulmonary hypertension, RVEF right ventricular ejection fraction
Continuous variables are expressed as mean ± standard
aStatistically significant differences between group A (control group) and group B
bstatistically significant differences between group C and group B
cstatistically significant differences between group A and group C
Fig. 3Right ventricular global circumferential strain rate (GCSR) values in the three groups. Among patients with preserved right ventricular ejection fraction, there was a significantly lower value for those with pulmonary hypertension (PH) (Group B) compared to those without PH (Group A)
Univariate analysis of the associations with the combined endpoint
| Variables | Death/Transplant/Worse NYHA ( | No endpoint ( |
|
|---|---|---|---|
| Clinical, CMR and hemodinamics variables | |||
| Age (yrs) | 53 ± 12 | 50 ± 12 | 0.35 |
| Sex (female) | 54 (69.2 %) | 27 (84.4 %) | 0.15 |
| Body surface area (m2) | 1.8 ± 0.25 | 1.7 ± 0.22 | 0.45 |
| Use of medication | 71 (91 %) | 10 (31 %) | <0.001 |
| Smoking | 5 (6.4 %) | 3 (9.4 %) | 0.059 |
| NYHA class ≥2 | 71 (91 %) | 3 (9.3 %) | <0.001 |
| Systolic aortic pressure (mm Hg) | 119 ± 18 | 127 ± 20.5 | 0.03 |
| PAWP (mm Hg) | 9.7 ± 4.2 | 10.1 ± 4.7 | 0.38 |
| Cardiac index (L/min/m2) | 3 ± 1 | 3.6 ± 1.57 | 0.04 |
| Systolic PA pressure (mm Hg) | 73.2 ± 20.3 | 58.1 ± 19.1 | 0.004 |
| Mean PA pressure (mm Hg) | 44.6 ± 11.8 | 27.5 ± 12.2 | <0.001 |
| RA pressure | 9.4 ± 7.9 | 6.4 ± 3.0 | 0.18 |
| PVRI (Woods units x m2) | 6.6 [3.9–10.3] | 2.4 [1.5–6.8] | 0.004 |
| PA sat (%) | 62 ± 11.6 | 71 ± 4.8 | 0.002 |
| LVEF (%) | 56.9 ± 10.8 | 62.5 ± 5.5 | <0.001 |
| LVEDVi (mL/m2) | 64 ± 18 | 72 ± 14 | 0.036 |
| LVESVi (mL/m2) | 27.7 ± 10.9 | 27.3 ± 6.7 | 0.82 |
| RVEF (%) | 37.38 ± 12.4 | 53.7 ± 9.4 | <0.001 |
| RVEDVi (mL/m2) | 112 [87.6–144.6] | 75 [69.9–97.9] | 0.01 |
| RVESVi (mL/m2) | 70 [44.9–95.4] | 35.2 [28.7–48.3] | <0.001 |
| RV mass index (gr/m2) | 29.8 [23.5–35.1] | 18.4 [14.3–22.9] | 0.001 |
| LGE | 39 (50 %) | 5 (15.6 %) | 0.01 |
| RA area | 26 ± 9.4 | 20 ± 5.8 | 0.001 |
| Strain parameters | |||
| GLS (%) | - 13.57 ± 5.5 | -19.01 ± 5.7 | <0.001 |
| GCS (%) | -9.6 ± 4.2 | -12.58 ± 3.7 | 0.007 |
| GLSR (s-1) | -0.94 ± 0.3 | -1.33 ± 0.4 | <0.001 |
| GCSR (s-1) | -0.67 [-0.7 - (-0.4)] | -0.92 [-1.1 - (-0.8)] | <0.001 |
Values are mean ± standard deviation, n (%), or median [interquartile range]
GCS global circumferential strain, GCSR global circumferential strain rate, GLS global longitudinal strain, GLSR global longitudinal strain rate, LGE late gadolinium enhancement, LVEF left ventricular ejection fraction, LVEDVi left ventricular end-diastolic volume index, LVESVi left ventricular end-systolic volume index, NYHA New York Heart Association, PA pulmonary artery, PAWP pulmonary artery wedge pressure, PVRI pulmonary vascular resistance index, RA right atrium, RVEDVi right ventricular end-diastolic volume index, RVEF right ventricular ejection fraction, RVESVi right ventricular end-systolic volume index
Cox proportional adjusted hazard ratio for final multivariate models of each RV strain parameter
| Models | Hazard ratio | 95 % Confidence Interval |
|
|---|---|---|---|
| GLS | 1.06 | 1–1.12 | 0.026 |
| Cardiac index | 0.59 | 0.4–0.79 | 0.030 |
| RV mass index | 1.02 | 1–1.04 | 0.006 |
| Mean PA pressure | 0.97 | 0.95–0.99 | 0.02 |
| ᅟ | |||
| RVEF | 0.97 | 0.94–0.99 | 0.03 |
| Cardiac index | 0.66 | 0.49–0.90 | 0.009 |
| RV mass index | 1.02 | 1–1.04 | 0.02 |
| Mean PA pressurea | 0.97 | 0.95–0.99 | 0.02 |
| ᅟ | |||
| GLSR | 2.52 | 1.03–6.1 | 0.04 |
| Cardiac index | 0.65 | 0.48–0.89 | 0.008 |
| RV mass index | 1.03 | 1.01–1.05 | 0.033 |
| ᅟ | |||
| GCSR | 4.5 | 1.3–15.6 | 0.01 |
| Cardiac index | 0.61 | 0.46–0.81 | 0.001 |
| RV mass index | 1.02 | 1–1.04 | 0.006 |
| Mean PA pressure | 0.97 | 0.95–0.99 | 0.01 |
aModel including global circumferential strain, not shown
GCSR global circumferential strain rate, GLS global longitudinal strain, GLSR global longitudinal strain rate, PA pulmonary artery, RVEF right ventricular ejection fraction
Fig. 4Kaplan Meyer survival curves for survival free of the combined endpoint according to CMR global RV strain parameters
Fig. 5Cox survival curve for survival free of the combined endpoint according to CMR global RV strain parameter cutoff point. GCSR cut off point > -0.8 s-1 was able to predict events in the multivariate model